The synergy solution: How public-private partnerships advance regenerative medicine
Our guests explain how public-private partnerships have impacted the regenerative medicine sector and helped to advance cell and gene therapies along the commercialization pathway.
Matthew Durdy, Chief Executive Officer, Cell and Gene Therapy Catapult
Michael May, PhD, President and Chief Executive Officer, CCRM
Public-private partnerships are collaborations between government agencies and private-sector companies. In this interview, Matthew Durdy, CEO, Cell and Gene Therapy Catapult, and Michael May, President and CEO, CCRM, explain how these collaborations have had an impact in the regenerative medicine sector by advancing cell and gene therapies along the commercialization pathway. Our guests share highlights from their organizations, including the types of partners they have worked with, and the infrastructure and facilities they have helped to create.
The interview concludes with a discussion of how public-private partnerships will benefit patients in the future by improving the factors that lead to market access and adoption, such as developing markets, promoting acceptability, reducing the cost of goods, and enabling the supply chain.
Spread the word about this episode by taking a screen cap on your device and posting it to social media using the hashtag #CCRMpodcast. Please leave us a review on your favourite streaming service.